[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,738,879
  • Shares Outstanding, K 37,275
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ 20 M
  • EBITDA $ 43 M
  • 60-Month Beta 0.26
  • Price/Sales 6.14
  • Price/Cash Flow 49.67
  • Price/Book 56.44

Options Overview Details

View History
  • Implied Volatility 78.66% (-3.05%)
  • Historical Volatility 50.84%
  • IV Percentile 64%
  • IV Rank 47.61%
  • IV High 110.75% on 08/07/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 34) 3.79 (8.13%)
  • Put/Call Vol Ratio 0.61
  • Today's Volume 1,085
  • Volume Avg (30-Day) 656
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 46,286
  • Open Int (30-Day) 47,523
  • Expected Range 42.86 to 50.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 3
  • High Estimate $0.01
  • Low Estimate $-0.50
  • Prior Year $0.24
  • Growth Rate Est. (year over year) -195.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.50 +15.19%
on 06/26/26
47.50 -1.79%
on 07/17/26
+4.71 (+11.23%)
since 06/17/26
3-Month
28.54 +63.45%
on 05/13/26
47.50 -1.79%
on 07/17/26
+5.15 (+12.41%)
since 04/17/26
52-Week
28.54 +63.45%
on 05/13/26
54.85 -14.95%
on 01/07/26
+10.51 (+29.08%)
since 07/17/25

Most Recent Stories

More News
Harrow Announces Commercial Launch of BYOOVIZ® in the United States

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ®...

HROW : 46.65 (+3.94%)
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers ...

HROW : 46.65 (+3.94%)
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 46.65 (+3.94%)
Harrow Q1 Earnings Call Highlights

Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized...

HROW : 46.65 (+3.94%)
Harrow: Q1 Earnings Snapshot

Harrow: Q1 Earnings Snapshot

HROW : 46.65 (+3.94%)
Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE...

HROW : 46.65 (+3.94%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 46.65 (+3.94%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 46.65 (+3.94%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 46.65 (+3.94%)
Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

NASHVILLE, Tenn., April 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 46.65 (+3.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Strengthening short term outlook on maintaining the current direction.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 51.55
2nd Resistance Point 49.53
1st Resistance Point 48.09
Last Price 46.65
1st Support Level 44.62
2nd Support Level 42.60
3rd Support Level 41.16

See More

52-Week High 54.85
Last Price 46.65
Fibonacci 61.8% 44.80
Fibonacci 50% 41.70
Fibonacci 38.2% 38.59
52-Week Low 28.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.